NewswireToday - /newswire/ -
Amherst, NH, United States, 2012/09/10 - Device sophistication and design ergonomics providing new opportunities for branding according to Greystone Research Associates - GreystoneAssociates.org.
The rapid evolution taking place within the injectable drug delivery sector – driven by biologicals and device technology advances – continues to effect changes throughout the supply chain and syringe/injector ecosystem. New classes of injection devices have opened the way to new forms of patient self-care, introducing a growing segment of consumers to parenteral drug self-administration. The changes are impacting the various device segments in different ways and to differing degrees.
The number of companies providing pre- and post fill/finish services to PFS suppliers and their drug developer partners continues to proliferate, due to the geographical nature of this business segment. For their part, PFS manufacturers, now primarily located in Europe, continue to establish syringe making facilities in strategic pharmaceutical and biotech regions, promoting the advantages of proximity and modern fabrication plant design. As they do, the supply chain follows, resulting in a spreading ecosystem with growing capabilities.
While the Pen injector supply market continues to be dominated by Ypsomed and a handful of other players, competition in this segment is growing, due to improvements in pen device design, reduced part counts and evolving state-of-the-art. On the therapeutic side, pens continue to dominate markets for insulin and hormone replacement. Pens are gaining ground in new therapeutic markets as a result of design wins for a number of recently approved drugs.
Leading suppliers of retractable safety syringes have made progress in lowering unit device cost, closing the gap between integrated safety syringes and adapted devices. The metamorphosis initiated by Unilife that is taking place with the convergence of safety and prefillable syringes, while still in its early stages, is expected to create opportunities for drug marketers by enabling the introduction of injectables that appeal to lay and professional users alike, while satisfying the need for caregiver safety.
Autoinjector designs continue to migrate toward disposables, creating branding opportunities for marketers and greater ease-of-use for patients. The evolution in autoinjector design is beginning to blur the distinction between pen injectors and autoinjector-enclosed prefilled syringes.
Recent progress in needle-free injector devices has come primarily from newer players pursuing niche markets. These companies are taking a page from the pen injector playbook, investing in tooling and technology to produce NFI devices that are esthetically pleasing and functionally advanced relative to previous generation NFIs
Detailed analysis of global injectable drug delivery markets is contained in a new and comprehensive report from Greystone. Injectable Drug Delivery to 2016: Drugs, Devices, Targets, Therapeutics and Forecasts documents and analyzes the results of a recent survey of injectable drug markets conducted by Greystone Research Associates.
Greystone Associates (greystoneassociates.org) is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.